Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025PRNewsWire • 04/22/25
Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/27/25
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate UpdatesPRNewsWire • 02/27/25
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025PRNewsWire • 02/13/25
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North CarolinaPRNewsWire • 12/23/24
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial GuidancePRNewsWire • 11/12/24
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 11/07/24
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of DirectorsPRNewsWire • 11/04/24
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024PRNewsWire • 10/29/24
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous FluidsPRNewsWire • 10/10/24
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")PRNewsWire • 09/25/24
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business OfficerPRNewsWire • 09/03/24
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/06/24
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial GuidancePRNewsWire • 08/06/24
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024PRNewsWire • 07/30/24
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment SystemPRNewsWire • 07/15/24
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 07/11/24
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")PRNewsWire • 07/02/24
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")PRNewsWire • 05/29/24